Business Context and Reporting Period
This Form 8-K filing by Altimmune, Inc. is dated November 27, 2018. The report discloses a significant change in executive leadership, specifically the departure of the President and Chief Executive Officer (CEO) and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: $500,000 annually for the new CEO.
- Signing Bonus: $100,000 lump sum cash payment (subject to claw-back).
- Target Bonus: Up to 55% of base salary, commencing January 1, 2019.
- Equity Grants:
- Incentive Stock Option with a grant-date fair value of $400,000.
- Non-qualified stock option for the remainder of 322,907 shares.
- 322,907 restricted shares of common stock.
- Commuting Reimbursement: Up to $36,000 per 12-month period (grossed up for taxes).
Material Changes
Executive Departure: William J. Enright resigned as President, CEO, and Board member, effective upon the appointment of his successor.
Executive Appointment: Vipin K. Garg, Ph.D., was appointed President, CEO, and Director, effective November 30, 2018. Dr. Garg previously served as President and CEO of Neos Therapeutics, Inc. and Tranzyme Pharma, Inc.
Outlook, Risks, and Contingencies
Severance Provisions:
- Without Cause/Good Reason: 12 months of base salary continuation, 12 months of health insurance, and payment of unpaid prior year's bonus.
- Change of Control: If termination occurs within one year of a change in control, Dr. Garg is entitled to 18 months of base salary, target bonus, 18 months of health insurance, and full acceleration of unvested equity awards.
Restrictive Covenants: Dr. Garg is subject to non-solicitation and non-compete restrictions for one year following termination.
Golden Parachute: Payments are subject to reduction if necessary to avoid the excise tax under Section 4999 of the Internal Revenue Code.
Investor Verification Checklist
- Verify the exact number of shares underlying the stock options by checking the stock price on the grant date (not provided in this text).
- Review the full Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause" and "Good Reason."
- Confirm the vesting schedule alignment with the company's fiscal calendar and performance milestones.
- Assess the impact of the $100,000 signing bonus and $36,000 commuting reimbursement on immediate cash flow.